Background: To search for novel biomarkers that can predict acute radiation toxicity, we conducted microRNA expression analysis of peripheral blood lymphocytes (PBLs). Methods: The discovery cohort was 69 patients with localized adenocarcinoma of the prostate who
Introduction
When radiotherapy is performed for the treatment of localized prostate cancer, a high dose needs to be delivered to the prostate while minimizing radiation of the surrounding normal organs/tissues (e.g., the rectum, urethra and bladder). Development of techniques such as three-dimensional conformal radiotherapy and intensity-modulated radiation therapy (IMRT) has allowed escalation of the dose delivered to the prostate, enhancing local tumor control without a significant increase of radiation toxicity (1) . Although acute radiation-induced gastrointestinal (GI) and genitourinary (GU) toxicities are usually manageable during radiotherapy, some patients require medical intervention (2) . If we could predict the risk of acute GI and GU radiation toxicity, dose fractionation and the target volume could be modified before treatment, especially in elderly patients.
There have been several reports about prediction of acute radiation toxicity with biological markers, such as predicting radiation dermatitis in patients receiving postoperative radiotherapy for breast cancer by using DNA single nucleotide polymorphisms (3) or predicting radiation esophagitis associated with chemo-radiotherapy for non-small cell lung cancer by using serum microRNA levels (4) . However, to the best of our knowledge, there have been no reports about biological markers that can predict acute complications of radiotherapy for prostate cancer.
MicroRNAs (miRNAs) are a class of small non-coding RNA molecules (21-25 nucleotides) involved in post-transcriptional regulation, which participate in the DNA damage response by regulating the expression of various target genes. Profiling studies have demonstrated that miRNA expression changes in response to radiation, while overexpression or knock-down of certain miRNAs has been shown to influence radiosensitivity (5) . MiRNAs also participate in the inflammatory response by regulating the expression of various target genes (6) (7) (8) .
In order to search for novel biomarkers that could help to predict radiation-induced acute GI or GU toxicities and facilitate personalized radiotherapy for prostate cancer, we conducted miRNA expression analysis in the peripheral blood lymphocytes (PBLs) of 69 prostate cancer patients receiving IMRT. Dose-volume histograms (DVH) and clinical variables were also examined to search for correlations between radiotherapy treatment planning parameters and acute toxicities. Another 72 prostate cancer patients treated with low-dose-rate brachytherapy (permanent iodine-125 seed implants) were also analyzed as a validation cohort.
Materials and methods
Discovery cohort: Between October 2007 and October 2010, 74 patients with localized adenocarcinoma of the prostate confirmed by biopsy received IMRT at our institution. Among them, four patients were lost to follow-up and one refused blood collection, so these five patients were excluded from analysis. As a result, 69 patients with follow-up for longer than 3 years who gave written informed consent to this study were eligible for analysis.
Validation cohort: this cohort was formed by 72 patients receiving low-dose-rate brachytherapy (using permanent iodine-125 seed implants) between May 2008 and March 2014, who were followed up for longer than 2 years.
Prostate cancer risk groups were classified according to the guideline of the National Comprehensive Cancer Network (9). This study was approved by our institutional review board.
Acute toxicities were assessed by medical chart review and were retrospectively confirmed by patient interview. All toxicities were graded according to the National Cancer Institute Common Terminology Criteria for Adverse Events (ver. 4.0).
In the IMRT group, acute toxicities were evaluated from start of radiotherapy to 3 months after completion of treatment. In the seed group, acute toxicities were evaluated from insertion of the radiation source to 6 months after the start of treatment.
As GI toxicities, proctitis, diarrhea and anal pain were assessed, while urinary frequency, incontinence and urgency were evaluated as GU toxicities.
The pretreatment urinary function score (PUFS) was calculated from the frequency of urination before radiotherapy, as well as difficulty with urination, dysuria, urgency, residual urine sensation and medications for urination.
None of the patients had bowel disease such as irritable bowel syndrome or inflammatory bowel disease such as Crohn's disease. Patient characteristics are listed in Table 1 .
We considered that Grade 1 GI toxicity and Grade 2 GU toxicity are not severe and are clinically manageable. However, there might still be an advantage to predicting such acute toxicity in some cases, especially elderly patients with poor bowel and/or urinary function.
Radiotherapy and review of DVH
Details of treatment planning and the results of DVH analysis were described in our previous report (10) . In brief, the median dose delivered to the planning target volume (PTV) during IMRT was 76 Gy in 38 fractions. For IMRT, we used 2D-bone matching with the ExacTrac system and a fiducial marker was not inserted. Treatment planning was mainly based on CT data and we used MRI when necessary, especially in patients with T3a and T3b disease (extracapsular invasion and seminal vesicle invasion). The rectum was contoured as a solid organ from the level of the ischial tuberosities to the rectosigmoid junction. The relative volume doses delivered to the rectum was calculated by using rectal DVHs.
For iodine-125 low-dose-rate brachytherapy, we set the treatment volume to include the prostate within the prescribed dose of 144 Gy, using a modified peripheral loading technique. Implantation was performed under lumbar anesthesia with transrectal ultrasonographic guidance. For DVH analysis, CT scans obtained 1 month after implantation were used. Dosimetric parameters calculated from the data included the minimal dose received by 90% of the prostate volume (D90), the rectal dose expressed as the volume that received >150% of the prescribed dose (RV150), and the urethral dose expressed as the volume that received >150% of the prescribed dose (UV150).
Harvesting PBLs
PBLs were collected at 3-7 years after the completion of radiation therapy. A single peripheral blood sample (10 ml) was obtained from each patient and collected in a sterile heparinized tube. PBLs were separated by centrifugation at 1500 rpm for 30 min at 4°C using Lymphoprep (Nycomed Pharma AS, Oslo, Norway). After separation of PBLs, the sample was divided into two parts. One was incubated for 4 h in RPMI-1640 medium (Sigma Aldrich, Taurtkirchen, Germany) supplemented with 20% fetal calf serum. The other was subjected to ex vivo irradiation with X-rays (120 kV at 1.17 Gy/min, 4 Gy) and then incubated for 4 h. This method separated lymphocytes and monocytes from whole blood, while excluding neutrophils and macrophages. Flowcytometry was performed on three representative samples, revealing the following cellular composition: 67 ± 5% T lymphocytes, 9 ± 6% B lymphocytes and 24 ± 10% monocytes.
Extraction of RNA and semiquantitative RT-PCR
Total RNA was extracted from PBLs by using a miRNeasy Kit (Qiagen, Valencia, CA, USA) and was used to synthesize firststrand cDNA (Life Technologies). Duplex PCR was performed with primers specific for the DNA-PKcs, Ku70, Ku80, and GAPDH genes. GAPDH served as the internal control and expression of each mRNA by PBLs was calculated as 2 − ΔCT, where ΔCT = (CT mRNA − CT GAPDH).
miRNA array analysis
A preliminary experiment was performed with the TaqMan ® Array
Human MicroRNA A Cards Set ver. 3.0 (Applied Biosystems, Foster City, CA, USA), which allows simultaneous measurement of the expression of 348 miRNAs with a microfluidic PCR platform. Four samples from patients with Grade 0-1 GI toxicity and four samples from patients with Grades 2-3 toxicity were tested. PCR was performed with a 7900HT Fast Real-Time PCR system (Applied Biosystems), and SDS 2.2.2 software (Applied Biosystems) was used for comparison of the cycle threshold (ΔCT). U6 snRNA (RNU6B, Applied Biosystems) served as the internal control. Expression of each miRNA by PBLs was calculated as 2 − ΔCT, where ΔCT = (CT miRNA − CT U6). As a result, 13 miRNAs were selected (miRNA-21, 28, 34a, 99a, 101, 155, 185, 221, 340, 410, 422a, 486 and 652) and these miRNAs were examined in all samples.
Quantitative RT-PCR of miRNAs
Expression of each miRNA was assessed by using TaqMan microRNA Assays (Applied Biosystems). In brief, 5 ng of total RNA was reverse transcribed using specific stem-loop RT primers, after which amplification and detection were performed by quantitative reverse transcription-PCR (qRT-PCR) with specific primers and TaqMan probes. PCR was done in triplicate using the 7500 Fast Real-Time PCR System (Applied Biosystems). SDS ver. 1.4 software (Applied Biosystems) was employed for calculation of ΔCT values with U6 as the internal control.
Statistical analysis
Student t-test was used to compare differences between two groups.
All P values were two-sided. To determine the optimal cut-off values for miRNA and gene expression, we performed receiver operating characteristics (ROC) analysis. Logistic regression analysis was performed to identify variables that influenced acute radiation toxicity after adjustment for confounders. Bellcurve for Excel ver 2.0 (SSRI, Japan) was employed for statistical calculations.
Results

Prediction of GI toxicity
In the IMRT group, 49 patients had Grade 0 acute GI toxicity, 18 patients had Grade 1 toxicity, and two patients had Grade 2 toxicity. The symptoms were pain during bowel movements in 14 patients, urgency of bowel movements in two patients, and diarrhea in four patients.
To examine the expression of candidate miRNAs predicting acute toxicity, PBLs from four patients each with Grade 0-1 late rectal toxicity and Grade 2-3 late rectal toxicity were selected for miRNA array analysis, as reported previously (11) . The preliminary study identified 13 candidate miRNAs, which are shown in Supplementary Table 1. Detailed raw data on miRNA expression in the IMRT and seed groups are described in Supplementary Tables 2  and 3 .
The relationship between acute GI toxicity and various parameters is shown in Table 2 . When the patients were divided into two groups (Grade 0 vs. Grade 1-2), univariate analysis showed borderline significance of the average prostate volume, the relative volume dose of 70 Gy delivered to the rectum (R70), Ku70 mRNA expression, constitutive expression of miR-101 and miR-410, and radiation-induced expression of miR-34a and miR-221, with P values ranging between 0.049 and 0.150. We also examined the C-reactive protein (CRP) level, prostate-specific antigen (PSA) level, WBC count and neutrophil/lymphocyte ratio (NLR) before radiation therapy, but there were not clear correlations with acute GI toxicity.
Since the expression of DNA-PKcs mRNA and Ku80 mRNA was correlated with Ku70 mRNA expression (r = 0.669 for DNAPKcs and r = 0.819 for Ku80, respectively), we excluded DNA-PKcs and Ku80 from further analysis.
ROC analysis was employed to determine cut-off values for the variables and the results are shown in Table 2 . After dichotomizing each variable at the respective cut-off value, the prostate volume, R70, constitutive expression of miR-101 and miR-410, and radiation-induced expression of miR-34a and miR-221 were assessed as predictors of Grade 1-2 acute GI toxicity by logistic regression analysis ( Table 3) . As a result, R70, constitutive miR-410 expression, and radiation-induced miR-221 expression were found to be significant risk factors for Grade 1-2 acute GI toxicity (P = 0.011 for R70, P = 0.020 for miR-410, and P = 0.013 for miR-221).
Finally, we generated ROC curves for models with the prostate volume, R70, miR-410, and miR-221 (Fig. 1a) . Compared with the model with prostate volume and R70, the area under the curve (AUC) was significantly increased (from 0.716 to 0.807, P = 0.017) by including the two miRNAs.
In order to validate the usefulness of these miRNAs for predicting toxicity, analysis was also carried out in the seed group. Of the 72 patients in this group, 61 patients had Grade 0 GI toxicity, eight patients had Grade 1 toxicity, and three patients had Grade 2 toxicity. The prostate volume, dose to 90% of the prostate (D90), volume of the rectum receiving 150% of the prescription dose (RV150), miR-410 expression, and miR-221 expression were investigated as predictors of acute GI toxicity. The cut-off values for the miRNAs were the same as those used in the IMRT group.
After dichotomizing each variable at the cut-off value, the prostate volume, D90, RV150, constitutive expression of miR-410 and radiation-induced expression of miR-221 were assessed by logistic regression analysis as predictors of Grade 1-2 acute GI toxicity ( Table 4) . As a result, D90 and constitutive miR-410 expression were shown to be significant predictors of Grade 1-2 acute GI toxicity (P = 0.045 for D90, P = 0.023 for miR-410).
Next, we generated ROC curves for models with the prostate volume, D90, RV150, miR-410 expression and miR-221 expression (Fig. 1b) . Compared with the model with prostate volume D90 and RV150, we found that the AUC was significantly increased (from 0.711 to 0.831, P = 0.032) by including the two miRNAs.
Prediction of GU toxicity
A total of 22 patients had Grade 0 acute GU toxicity, 18 patients had Grade 1 toxicity, and 29 patients had Grade 2 toxicity. Symptoms were frequent urination in 30 patients, dysuria in 10, urine urgency in 3, urinary incontinence in 3, urination difficulty in 3, and hematuria in 1. Among them, 29 patients needed medications for their symptoms.
GI toxicities tended to be less severe than GU toxicities since the gastrointestinal tract (rectum) was not included in the PTV for IMRT, but part of the urethra and bladder were inside the PTV. Therefore, we grouped GI toxicity as Grade 0 vs. Grades 1-2, but grouped GU toxicity as Grades 0-1 vs. Grade 2.
The relationship between acute GU toxicity and various parameters is shown in Table 5 . When the patients were divided into two groups (Grades 0-1 vs. Grade 2), univariate analysis showed that the average prostate volume; mean PTV dose; maximum dose to the urinary bladder (Bmax); PUFS; expression of Ku70 and Ku80 mRNA; and constitutive expression of miR-99a, miR-185, miR-221 and miR-340 were significant factors, with P values ranging between 0.006 and 0.050. In contrast, the CRP, PSA, WBC count and NLR before radiation therapy were not associated with the severity of acute GU toxicity.
Since Ku70 and Ku80 mRNA expression were strongly correlated, we excluded Ku70 from further analysis. The mean PTV dose and Bmax were also strongly correlated (r = 0.839), so we excluded the mean PTV dose from further analysis as well.
As with GI toxicity, ROC analysis was employed to determine cut-off values for these variables and the results are shown in Table 5 . After dichotomizing each parameter at the cut-off value; the prostate volume; B max ; constitutive expression of miR-99a, miR-185, miR-221 and miR-340; and radiation-induced expression of miR-101 were assessed by logistic regression analysis as predictors of Grade 2 acute GU toxicity (Table 6) . While prostate volume, B max , miR-99a expression and miR-221 expression were related to the occurrence of Grade 2 acute GU toxicity, the relation did not reach statistical significance for any of these parameters.
We generated ROC curves for models with the prostate volume, PUFS, Bmax, miR-99a expression, and miR-221 expression as predictors of Grade 2 of acute GU toxicity (Fig. 2a) . Compared with the model with prostate volume, Bmax, and PUFS, the AUC was increased (from 0.754 to 0.796) by including the two miRNAs, but the improvement was not significant (P = 0.330).
To validate the usefulness of these miRNAs for predicting toxicity, analysis was also carried out in the seed group. Of the 72 patients in this group, 13 patients had Grade 0 GU toxicity, 28 patients had Grade 1 toxicity, and 31 patients had Grade 2 toxicity. Prostate volume, D90, volume of the urethra receiving 150% of the prescription dose (UV150), PUFS, miR-99a expression, and miR-221 expression were tested as predictors of acute GU toxicity. The cut-off values of the miRNAs were the same as those used in the IMRT group.
After dividing the patients at each cut-off value, the prostate volume, D90, UV150, PUFS, miR-99a expression and miR-221 expression were assessed as predictors of Grade 2 acute GU toxicity by logistic regression analysis ( Table 7) . As a result, none of these parameters were found to be significant risk factors for Grade 2 acute GU toxicity.
Then, we generated ROC curves for models with the prostate volume, D90, UV150, PUFS, miR-410 expression and miR-221 expression (Fig. 2b) . Compared with the model with prostate volume D90, UV150 and PUFS, the AUC was increased (from 0.656 to 0.714) by including the two miRNAs. However, the increase was not statistically significant (P = 0.166).
Discussion
According to our literature search, this is the first study about prediction of acute GI and GU radiation toxicities that has focused on miRNA expression. Improving the ability to predict severe side effects of radiotherapy would allow identification of patients who may benefit from early intervention or prophylaxis for acute complications.
Ideally, cells from GU and GI tissues would be used for assessment of miRNA expression to predict acute radiation toxicity, but harvesting such cells is invasive and difficult. We previously determined that about 50-100 times more miRNA can be isolated from PBLs compared with the level of miRNA in serum exosomes (unpublished data). Because miRNAs are abundant in PBLs, analysis is easy. In addition, PBLs can be used to assess miRNAs derived from normal tissues, while tumor-derived miRNAs may contaminate serum exosomes (12) . Accordingly, we employed PBLs instead of serum for miRNA profiling. We also assumed that PBLs can be used as a surrogate for other cell types, such as GI and GU cells, because we previously demonstrated that low constitutive Ku80 mRNA expression and high radiation-induced miRNA-99a expression by PBL were associated with late complications of radiotherapy (late rectal bleeding) in prostate cancer patients receiving IMRT (11), suggesting that miRNA expression by PBLs could be a promising marker for predicting late complications. Examination of PBLs has several benefits, such as being less invasive and more rapid compared with cells from other normal tissues. There have also been reports that PBLs can used to predict the radiosensitivity of normal tissues (13) . It is known that specific miRNAs are involved in regulating immune responses and immune cell development, which are crucial to the pathogenesis of various inflammatory diseases (14) . Since acute radiation complications are closely related to inflammation, patients who show alterations of miRNA expression associated with inflammation could develop more severe toxicities through interactions between PBLs and the GI or GU tissues. There have already been several reports that the increase of CRP and various cytokines during treatment (rather than the levels before treatment) is associated with the severity of acute toxicity due to radiotherapy in patients with prostate cancer or head and neck cancer (15) (16) (17) . However, the novel point of our study was prediction of acute toxicity by examining miRNA expression in PBLs before radiotherapy, which would allow toxicity to be predicted at an earlier time than other methods.
We found that the accuracy of predicting acute GI toxicity was significantly improved by adding miRNA expression to radiation dose parameters in both the IMRT group (discovery cohort) and the seed group (validation cohort). Logistic regression analysis showed that lower constitutive miR-410 expression and lower radiationinduced miR-221 expression were associated with a higher frequency of Grades 1-2 GI toxicity (Tables 2 and 3 ). ROC analysis revealed that the combination of prostate volume, R70, miR-410 expression and miR-221 expression had a significantly higher AUC value compared with prostate volume and R70 only (Fig 1a) . Experimental data have suggested that miRNA-410 and miRNA-221 are related to inflammation. MiRNA-410 down-regulates VEGF expression through interaction with VEGF mRNA and overexpression of miRNA-410 may effectively suppress VEGF expression (18) . Inflammation associated with radiotherapy is partly mediated via increased vascular permeability that is caused by damage to capillary endothelial cells, leading to edema (19) . Increased expression of miRNA-410 would inhibit VEGF expression, which might help to suppress inflammation, and could be related to the higher frequency of Grades 1-2 GI toxicity in patients with lower constitutive miRNA-410 expression.
MiRNA-221 had multiple roles and could affect the GI and GU organs differently. In experiments with mesenchymal stromal cells from the human forehead, addition of an inflammatory cocktail resulted in a 15-fold decrease of miRNA-221 expression (20) . Such down-regulation of miRNA-221 by inflammatory signals might explain why radiation-induced miRNA-221 expression was higher in patients with Grade 0 GI toxicity than in those with Grades 1-2 ROC, receiver operating characteristics; B max , maximum dose to the urinary bladder; B x , relative volume dose of x Gy delivered to the bladder; PUFS, pretreatment urinary function score; NLR, neutrophil/lymphocyte ratio. GI toxicity. It was reported that miRNA-221 promotes endothelial inflammation by targeting adiponectin receptor 1, which mediates endothelial nitric oxide production (21) . This effect might be related to the higher frequency of Grade 2 GU complications in patients with higher constitutive miRNA-221 expression.
Regarding GU toxicity in the IMRT group (discovery cohort), logistic regression analysis showed that PUFS and elevated constitutive expression of miR-99a and miR-221 were associated with a higher frequency of Grade 2 GU toxicity (Tables 5 and 6 ). However, addition of miR-99a and miR-221 to the model did not significantly increase the AUC for prediction of GU toxicity in ROC analysis compared with the model with prostate volume, PUFS and Bmax (Fig. 2a) . It is possible that the influence of PUFS was too strong and obscured the influence of the two miRNAs. Likewise, prediction of GU toxicity was not improved by adding these miRNAs to the logistic model in the seed group (validation cohort) (Fig. 2b) . During seed implantation, 10-15 needles are inserted transperineally to embed radioactive sources in the prostate gland. It is possible that physical stimulation of the GU system by this seed insertion technique has a greater influence on acute adverse events than the biological effects of radiation.
Kerns et al. investigated prediction of GI toxicity by genomewide analysis of single nucleotide polymorphisms (SNPs) in patients treated with EBRT and/or seed implants (50% seed alone and 50% seed + EBRT in the discovery cohort vs. 8% seed alone and 92% EBRT alone in the validation cohort). The AUC for prediction of GI toxicity was 0.892 in the discovery cohort and 0.737 in the validation cohort (13) . We referred to their study when designing the present investigation. The most important finding of our study was that, even for different modalities with different dose rates like EBRT and seed implants, it was possible to predict acute GI toxicity more accurately by combining clinical parameters (PV + R70 for IMRT or PV + R100 for seed implants) with expression of two miRNAs.
We chose prostate cancer for prediction of toxicity because it is easy to evaluate the effect of radiotherapy since patients do not receive concomitant chemotherapy and the treatment plan is relatively uniform.
This study had some limitations, such as the small patient population and collection of samples after completion of radiotherapy. Experiments on therapeutic radiotherapy using cancer cell lines have suggested that radiation might cause alterations of miRNA expression both during and after radiotherapy (22) . In order to avoid this effect, we collected PBLs for this study at 3-7 years after completion of radiotherapy. However, the initial radiation exposure, subsequent toxicity, further treatment and lifestyle changes after diagnosis of cancer may have influenced miRNA expression in unknown ways. Therefore, we are now performing a prospective study in which PBLs are harvested immediately before and after treatment to compare miRNA expression.
In conclusion, a combination of radiation dose parameters and miRNA expression by PBLs may be useful for predicting acute GI toxicity, which could contribute to personalized treatment of prostate cancer.
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